The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Stephen Nimer on MSI2 as a Requirement for Maintaining Activated MDS Stem Cells

Stephen Nimer, MD
Published Online: 6:08 PM, Sun December 6, 2015


Stephen D. Nimer, MD, leukemia and lymphoma treatment specialist, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses results of a study which examined Musashi2 (MSI2) as a requirement for maintaining activated myelodysplastic syndrome (MDS) cells. MSI2 is an RNA-binding protein expressed in hematopoietic stem cell.


Studies in MSI2 have shown that as MDS progresses to AML, cells express higher levels of MSI2, suggesting that MSI2 must confer some benefit to the cells, according to Nimer. He adds that without MSI2, MDS cannot be sustained, while on the other end of the spectrum, patients with an overabundance of MSI2 quickly develop leukemia.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.